Luye Pharma Group Stock Return On Asset

LYPHF Stock  USD 0.34  0.00  0.00%   
Luye Pharma Group fundamentals help investors to digest information that contributes to Luye Pharma's financial success or failures. It also enables traders to predict the movement of Luye Pink Sheet. The fundamental analysis module provides a way to measure Luye Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Luye Pharma pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Luye Pharma Group Company Return On Asset Analysis

Luye Pharma's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Luye Pharma Return On Asset

    
  0.0081  
Most of Luye Pharma's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Luye Pharma Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Luye Pharma Group has a Return On Asset of 0.0081. This is 100.09% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on asset for all United States stocks is 105.79% lower than that of the firm.

Luye Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Luye Pharma's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Luye Pharma could also be used in its relative valuation, which is a method of valuing Luye Pharma by comparing valuation metrics of similar companies.
Luye Pharma is currently under evaluation in return on asset category among its peers.

Luye Fundamentals

About Luye Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Luye Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Luye Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Luye Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Luye Pink Sheet

Luye Pharma financial ratios help investors to determine whether Luye Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Luye with respect to the benefits of owning Luye Pharma security.